哌罗匹隆与奎硫平对首发精神分裂症治疗的对照研究

Control study on perospirone and quetiapine in the treatment of the first-episode schizophrenia

目的:探讨哌罗匹隆治疗首发精神分裂症的疗效与安全性。方法:将59例符合中国精神障碍分类与诊断标准第3版(CCMD-3)精神分裂症诊断标准的患者随机分为哌罗匹隆组与喹硫平组,于治疗前及治疗2、4、6周末进行阳性与阴性症状量表(PANSS)评定,并记录不良反应。结果:哌罗匹隆组有效率与喹硫平组有效率比较,差异无统计学意义(P>0.05),两组不良反应发生率相当,差异无统计学意义(P>0.05)。结论:哌罗匹隆治疗精神分裂症安全有效。

Objective：To evaluate the clinical et/icacy and safety of perospirone in the treatment of schizophrenia. Methods： 59 first- episode schizophrenic patients were randomly divided into perospirone group and quetiapine group. Positive and negative syndrome scale （PANSS）was used to assess their curative effect. The adverse event rating scale was used to assess the safety of the treatment. Results： Comparison with the effective rate of perospirone group and that of quetiapine group, the difference showed no significant difference （P〉0.05）, There was no significant difference between two groups in side effects （P〉0.05）.Conclusion perospirone is safe and effective in treatment of first-episode schizophrenia.